Lantheus Holdings, Inc.
LNTH
Rang in aandelen
#2849
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the... Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Aandeelprijs
$100.02
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$6.53B
Verandering (1 dag)
0.32%
Verandering (1 jaar)
76.71%
Land
US
Handel Lantheus Holdings, Inc. (LNTH)
Categorie
Healthcare
Winst voor Lantheus Holdings, Inc. (LNTH)
Winst in Jun 2026 TTM: $362.98M
Volgens de meest recente financiële verslagen van Lantheus Holdings, Inc. bedraagt de huidige winst van het bedrijf $362.98M. In 2023 behaalde het bedrijf een winst van $410.94M, een stijging ten opzichte van de winst van 2022, die $26.72M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Lantheus Holdings, Inc. van 2011 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $362.98M | -15.78% |
| 2024 | $430.98M | 4.88% |
| 2023 | $410.94M | 1,438.02% |
| 2022 | $26.72M | -135.61% |
| 2021 | $-75.04M | 553.70% |
| 2020 | $-11.48M | -140.10% |
| 2019 | $28.63M | -42.22% |
| 2018 | $49.55M | 25.00% |
| 2017 | $39.64M | 40.10% |
| 2016 | $28.29M | -340.23% |
| 2015 | $-11.78M | 397.80% |
| 2014 | $-2.37M | -96.09% |
| 2013 | $-60.54M | 42.26% |
| 2012 | $-42.56M | -19.97% |
| 2011 | $-53.18M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 386.13% |
IN
|
